首页> 美国卫生研究院文献>Journal of Ophthalmology >25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy
【2h】

25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy

机译:25号微切口玻璃体切割术治疗小梁切除术后青光眼的玻璃体视网膜疾病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose. To determine the feasibility of using 25-gauge microincision vitrectomy surgery (25GMIVS) to treat vitreoretinal disease in glaucomatous eyes which have previously undergone trabeculectomy (TLE). Methods. A consecutive, interventional case series. We performed 25GMIVS in 15 glaucomatous eyes that had undergone TLE. Follow-up period was 11.5 months. Results. 25GMIVS was successfully used and led to improvement in visual acuity (P < 0.01). We performed 25GMIVS for proliferative diabetic retinopathy with neovascular glaucoma in 53% of eyes (8 of 15). Although 3 eyes needed further TLE following 25GMIVS, final IOP was below 21 mmHg in all eyes except one eye (93%) and was comparable to pre-25GMIVS IOP (P = 0.20) without an increase in the number of glaucoma medications (P = 0.14). Conclusions. 25GMIVS is a feasible treatment for vitreoretinal disease in eyes with preexisting TLE, effective in both significantly improving BCVA and preserving the filtering bleb, while not excluding further glaucoma surgery.
机译:目的。为了确定使用25规格显微切割玻璃体切除术(25GMIVS)来治疗先前接受过小梁切除术(TLE)的青光眼的玻璃体视网膜疾病的可行性。方法。连续的介入病例系列。我们在经历过TLE的15眼青光眼中进行了25GMIVS。随访时间为11.5个月。结果。成功使用25GMIVS并导致视敏度提高(P <0.01)。我们对53%的眼睛(15人中的8人)进行了25GMIVS来治疗增生性糖尿病视网膜病变伴新生血管性青光眼。尽管25GMIVS后有3眼需要进一步的TLE,但除一只眼外,所有眼睛的最终IOP均低于21 mmHg(93%),与25GMIVS之前的IOP相当(P = 0.20),而青光眼药物的使用量却没有增加(P = 0.14)。结论。 25GMIVS是一种治疗已经存在TLE的眼睛的玻璃体视网膜疾病的可行方法,对显着改善BCVA和保留滤过泡均有效,但不排除进一步的青光眼手术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号